This post is also available in:
English
A round of applause for our research site physicians Dr Sam Henein and Dr Michael O’Mahony for their participation in the Amarin REDUCE-IT hypertriglyceridemia study! After more than a decade of development and testing, VAZKEPA becomes the first and only European Commission-approved treatment to reduce cardiovascular risk in high-risk, statin-treated adult patients who have elevated triglycerides and other risk characteristics as studied in REDUCE-IT. Keep up the amazing work guys 